Close

Synergy Pharma (SGYP) IBS-C Risk Level Low, Outlook Solid; Aegis Boosts PT to $28

March 24, 2014 1:05 PM EDT Send to a Friend
Aegis Capital affirms Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP) at Buy and raises its price target from $25 up to $28 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login